Ambrisentan

Ambrisentan
Clinical data
Trade names	Letairis, Volibris, Pulmonext
AHFS/Drugs.com	Monograph
MedlinePlus	a612023
License data	US DailyMed: Ambrisentan;
Pregnancy; category	AU: X (High risk);
Routes of; administration	By mouth
ATC code	C02KX02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	99%
Elimination half-life	15 hours (terminal)
Identifiers
	IUPAC name (2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid;
CAS Number	177036-94-1 ;
PubChem CID	6918493;
IUPHAR/BPS	3951;
DrugBank	DB06403 ;
ChemSpider	5293690 ;
UNII	HW6NV07QEC;
KEGG	D07077;
ChEBI	CHEBI:135949;
ChEMBL	ChEMBL1111 ;
CompTox Dashboard (EPA)	DTXSID4046282 ;
ECHA InfoCard	100.184.855
Chemical and physical data
Formula	C22H22N2O4
Molar mass	378.428 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H](Oc1nc(cc(n1)C)C)C(OC)(c2ccccc2)c3ccccc3;
	InChI InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1 ; Key:OUJTZYPIHDYQMC-LJQANCHMSA-N ;
	(verify)

Ambrisentan, sold under the brand name Letairis among others, is a drug used for the treatment of pulmonary hypertension. It is an endothelin receptor antagonist.

The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ET_A). Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind, multicenter trials (ARIES-1 and ARIES-2). Like all endothelin receptor antagonists, Ambrisentan is contraindicated in pregnant women as well as those who are trying to become pregnant, due to the potential for teratogenic effects on the fetus.

Ambrisentan was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and designated an orphan drug, for the treatment of pulmonary hypertension.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.